EUVIMEDEUVIMED entdecken
Crossref

Identification of the In Vitro and In Vivo Metabolites of Chrysotoxine Using Liquid Chromatography Combined With Benchtop Orbitrap High‐Resolution Mass Spectrometry

Chengzhen Guan, Yiqiang An, Meiling Wan iD

Rapid Communications in Mass Spectrometry · 2025

DOI: 10.1002/rcm.10137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2025. Verfasst von Chengzhen Guan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Bibenzyls. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Chrysotoxine, a bibenzyl derivative from the stems of Dendrobium medicinal herbs, has recently emerged as a promising therapeutic candidate for cervical cancer. This study aimed to characterize chrysotoxine metabolites across multiple hepatocyte species and in rat urine.

Methods

Metabolites were identified and characterized using liquid chromatography coupled with benchtop Orbitrap high‐resolution mass spectrometry (LC–Orbitrap–MS/MS) combined with Compound Discoverer software. Structural elucidation relied on accurate mass measurements (mass error < 5 ppm) and comprehensive MS 2 fragmentation pattern interpretation.

Results

Twelve distinct metabolites were structurally identified. Among these, M4, M6, M7, M8, M10, M11, and M12 are newly reported. Metabolic transformations occurred via five principal pathways: hydroxylation, demethylation, glucuronidation, sulfation, and glutathione (GSH) conjugation. Cross‐species analysis of hepatocytes revealed direct glucuronidation as the predominant metabolic reaction. Urinary excretion profiles in rats identified hydroxylated (M9) and glucuronidated (M11) metabolites as the major elimination products. During the metabolism, chrysotoxine can be metabolized into quinone methide and ortho quinone intermediates that can be conjugated with GSH, forming the adducts M1, M2, M3, and M5.

Conclusions

This study delineates chrysotoxine metabolites in vitro and in vivo, providing critical insights for further pharmacokinetic and toxicity assessments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryBibenzylsAnimalsRatsRats, Sprague-DawleyHepatocytesChromatography, LiquidMaleHumansChromatography, High Pressure Liquid

Stichwörter der Autor:innen

DendrobiumLC–Orbitrap–MS/MSchrysotoxinemetabolite characterization

Substanzen

Bibenzyls

Autor:innen und Institutionen

  • Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • The Health Policy Research Institute of Xuzhou Medical University, Xuzhou, China.

ORCID-Profile: Meiling Wan

Zitieren

APA

Guan, C., An, Y., & Wan, M. (2025). Identification of the In Vitro and In Vivo Metabolites of Chrysotoxine Using Liquid Chromatography Combined With Benchtop Orbitrap High‐Resolution Mass Spectrometry. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.10137

Vancouver

Guan C, An Y, Wan M. Identification of the In Vitro and In Vivo Metabolites of Chrysotoxine Using Liquid Chromatography Combined With Benchtop Orbitrap High‐Resolution Mass Spectrometry. Rapid Communications in Mass Spectrometry. 2025. doi:10.1002/rcm.10137

BibTeX
@article{Guan2025,
  author = {Guan, Chengzhen and An, Yiqiang and Wan, Meiling},
  title = {Identification of the In Vitro and In Vivo Metabolites of Chrysotoxine Using Liquid Chromatography Combined With Benchtop Orbitrap High‐Resolution Mass Spectrometry},
  journal = {Rapid Communications in Mass Spectrometry},
  year = {2025},
  doi = {10.1002/rcm.10137}
}
Kostenlos starten →